Published in J Immunol on July 15, 1994
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion. PLoS Pathog (2013) 1.65
The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest (2004) 1.53
IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site. J Clin Invest (2001) 1.39
Mouse hepatitis virus-specific cytotoxic T lymphocytes protect from lethal infection without eliminating virus from the central nervous system. J Virol (1995) 1.34
Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. J Immunol (2008) 1.27
Distribution of mouse adenovirus type 1 in intraperitoneally and intranasally infected adult outbred mice. J Virol (1998) 1.20
La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J Virol (1999) 1.15
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst (2008) 1.12
Role of T cells and dendritic cells in glomerular immunopathology. Semin Immunopathol (2007) 1.08
Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J Virol (1999) 1.06
Virus-specific and bystander CD8 T cells recruited during virus-induced encephalomyelitis. J Virol (2005) 1.04
Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site. J Virol (2001) 1.04
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res (2009) 1.01
DNA-based vaccination induces humoral and cellular immune responses against hepatitis B virus surface antigen in mice without activation of C-myc. World J Gastroenterol (2000) 0.92
Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity. Immunology (2014) 0.89
Antigen presentation in retroviral vector-mediated gene transfer in vivo. Proc Natl Acad Sci U S A (1997) 0.88
Blockade of neutrophil elastase attenuates severe liver injury in hepatitis B transgenic mice. J Virol (2005) 0.85
Plasmodium cellular effector mechanisms and the hepatic microenvironment. Front Microbiol (2015) 0.84
Spatiotemporal dynamics of effector CD8+ T cell responses within the liver. J Leukoc Biol (2015) 0.76
Immunoregulation of hepatitis B virus infection--rationale and clinical application. Nagoya J Med Sci (2012) 0.76
Role of T cell death in maintaining immune tolerance during persistent viral hepatitis. World J Gastroenterol (2013) 0.76
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
In yeast, RAS proteins are controlling elements of adenylate cyclase. Cell (1985) 11.63
Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J (1999) 10.82
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity (1996) 8.27
Viral clearance without destruction of infected cells during acute HBV infection. Science (1999) 6.78
High-level hepatitis B virus replication in transgenic mice. J Virol (1995) 5.81
Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol (2001) 5.81
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer (1998) 5.40
WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. EMBO J (1996) 5.24
Isolation and characterization of yeast mutants deficient in adenylate cyclase and cAMP-dependent protein kinase. Proc Natl Acad Sci U S A (1982) 5.04
Differential regulation of mammalian period genes and circadian rhythmicity by cryptochromes 1 and 2. Proc Natl Acad Sci U S A (1999) 4.62
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination. EMBO J (1997) 4.01
Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med (2000) 3.93
Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology (1999) 3.73
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med (1996) 3.60
Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest (1995) 3.47
HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol (1993) 3.42
Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet (1998) 3.38
CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol (2000) 3.36
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A (1994) 3.34
Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science (1990) 3.26
Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase. J Biol Chem (1987) 3.20
Expression of hepatitis B virus surface and core antigens: influences of pre-S and precore sequences. J Virol (1987) 3.16
Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med (1993) 3.06
The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun (1991) 3.04
Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A (1988) 2.99
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis (2000) 2.98
Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol (1986) 2.94
Initiation of meiosis in yeast mutants defective in adenylate cyclase and cyclic AMP-dependent protein kinase. Cell (1983) 2.91
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet (1999) 2.81
Genetic analysis of the role of cAMP in yeast. Yeast (1985) 2.78
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 2.70
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A (1996) 2.68
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest (1996) 2.65
Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol (2000) 2.65
Transmission of type B viral hepatitis to chimpanzees. J Infect Dis (1973) 2.51
Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol (1997) 2.50
HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med (1993) 2.49
Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol (2000) 2.49
Control of cell division in Saccharomyces cerevisiae mutants defective in adenylate cyclase and cAMP-dependent protein kinase. Exp Cell Res (1983) 2.48
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol (1996) 2.47
A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science (1985) 2.47
Liver tumor promotion by the cyanobacterial cyclic peptide toxin microcystin-LR. J Cancer Res Clin Oncol (1992) 2.40
Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology (2001) 2.38
Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A (2000) 2.36
Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology (1992) 2.31
Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol (1992) 2.25
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res (1998) 2.22
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science (1985) 2.18
Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 2.11
Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest (1994) 2.10
Identification of the structural gene and nonsense alleles for adenylate cyclase in Saccharomyces cerevisiae. J Bacteriol (1984) 2.09
Mercury and cadmium resistances mediated by the penicillinase plasmid in Staphylococcus aureus. J Bacteriol (1974) 2.09
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol (1998) 2.06
To kill or to cure: options in host defense against viral infection. Curr Opin Immunol (1996) 2.06
Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol (1994) 2.05
Cyclic AMP may not be involved in catabolite repression in Saccharomyes cerevisiae: evidence from mutants capable of utilizing it as an adenine source. J Bacteriol (1982) 2.05
Heat shock response of Saccharomyces cerevisiae mutants altered in cyclic AMP-dependent protein phosphorylation. Mol Cell Biol (1987) 2.05
Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest (1996) 2.04
The fine structure of the horizontal cells in some vertebrate retinae. Cold Spring Harb Symp Quant Biol (1965) 1.98
Visualization of substrate binding and translocation by the ATP-dependent protease, ClpXP. Mol Cell (2000) 1.98
Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest (1996) 1.96
Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest (1995) 1.95
Abdominal ultrasonography for the diagnosis of strangulation in small bowel obstruction. Br J Surg (1994) 1.95
Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines. J Virol (1992) 1.94
Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J Virol (1994) 1.94
High incidence of ultraviolet-B-or chemical-carcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group A gene. Nature (1995) 1.91
The metabolic topography of parkinsonism. J Cereb Blood Flow Metab (1994) 1.89
Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol (1987) 1.85
gp180, a host cell glycoprotein that binds duck hepatitis B virus particles, is encoded by a member of the carboxypeptidase gene family. J Biol Chem (1995) 1.83
X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res (1999) 1.81
Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A (1994) 1.79
A mouse model of a human multiple GIST family with KIT-Asp820Tyr mutation generated by a knock-in strategy. J Pathol (2008) 1.78
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroenterol (2001) 1.77